Literature DB >> 32165071

The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin.

Tetsuo Yamaguchi1, Hiroe Konishi2, Kotaro Aoki3, Yoshikazu Ishii3, Koji Chono4, Kazuhiro Tateda3.   

Abstract

OBJECTIVE: To investigate the effect of vancomycin and fidaxomicin on the diversity of intestinal microbiota in a mouse model of Clostridioides difficile infection.
METHODS: Mice were divided into 11 models (4 mice per model): 6 uninoculated models and 5 models inoculated with C. difficile BI/NAP1/027. Inoculated models were prepared using intraperitoneal clindamycin followed by inoculation with C. difficile BI/NAP1/027. Uninoculated and C. difficile-inoculated mice received 2 or 7 days' vancomycin or fidaxomicin. Clostridium butyricum MIYAIRI 588 probiotic and lactoferrin prebiotic were administered for 10 days to uninoculated mice. Intestinal microbiome composition was investigated by sequence analyses of bacterial 16S rRNA genes from faeces, and microbiota diversity estimated.
RESULTS: In uninoculated, untreated ('normal') mice, Clostridia (57.8%) and Bacteroidia (32.4%) accounted for the largest proportions of gut microbiota. The proportion of Clostridia was numerically reduced in C. difficile-inoculated versus normal mice. Administration of vancomycin to C. difficile-inoculated mice reduced the proportions of Bacteroidia and Clostridia, and increased that of Proteobacteria. Administration of fidaxomicin to C. difficile-inoculated mice reduced the proportion of Clostridia to a lesser extent, but increased that of Bacteroidia. Microbiota diversity was lower in C. difficile-inoculated versus normal mice (164.5 versus 349.1 operational taxonomic units (OTUs), respectively); treatment of C. difficile-inoculated mice with 7 days' vancomycin reduced diversity to a greater extent than did 7 days' fidaxomicin treatment (26.2 versus 134.2 OTUs, respectively).
CONCLUSIONS: Both C. difficile inoculation and treatment with vancomycin or fidaxomicin reduced microbiota diversity; however, dysbiosis associated with fidaxomicin was milder than with vancomycin.
Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  16S rRNA; Clostridioides difficile; Fidaxomicin; Microbiota

Year:  2020        PMID: 32165071     DOI: 10.1016/j.jiac.2019.12.020

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  3 in total

Review 1.  Application of Microbiome Management in Therapy for Clostridioides difficile Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents.

Authors:  Chun-Wei Chiu; Pei-Jane Tsai; Ching-Chi Lee; Wen-Chien Ko; Yuan-Pin Hung
Journal:  Pathogens       Date:  2021-05-24

2.  Antibiotic administration in targeted nanoparticles protects the faecal microbiota of mice.

Authors:  Baris A Borsa; Mert Sudagidan; Mehmet E Aldag; Isik I Baris; Elif E Acar; Cagatay Acuner; Murat Kavruk; Veli C Ozalp
Journal:  RSC Med Chem       Date:  2021-01-15

3.  The Initial Gut Microbiota and Response to Antibiotic Perturbation Influence Clostridioides difficile Clearance in Mice.

Authors:  Sarah Tomkovich; Joshua M A Stough; Lucas Bishop; Patrick D Schloss
Journal:  mSphere       Date:  2020-10-21       Impact factor: 4.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.